MedPage Today

Oral Microbiome Therapy Tied to Low Recurrence of C. Diff

A potential first-in-class investigational microbiome therapeutic, SER-109, was safe and observed to sustain low Clostridioides difficile (C. diff) recurrence rates for adults, according to the phase ...
Science Daily

New live bacterial product for stubborn superbug improves quality of life

SER-109 is a pill with live, purified Firmicutes bacterial spores designed to compete metabolically with C. diff and restore colonization resistance to C. diff. In the world of superbugs (bacteria ...
Medicine Buffalo

UB scientist is co-author on NEJM paper demonstrating how an oral microbiome therapy prevents recurrent C. difficile infections

BUFFALO, N.Y. — People who develop colitis with the virulent bacterium C. difficile, usually after a course of antibiotics or chemotherapy, experience severe diarrhea, inflammation of the colon and ...
MedPage Today

Frozen or Powdered: Fecal Transplant Works in C. Diff

PHILADELPHIA -- Frozen or lyophilized specimens may offer an effective and convenient alternative to fresh stool samples for fecal transplant in patients with recurrent episodes of Clostridium ...
Medicine Buffalo

UB scientist co-author of paper outlining therapy for preventing recurrent C. difficile infections

People who develop colitis with the virulent bacterium C. difficile, usually after a course of antibiotics or chemotherapy, experience severe diarrhea, inflammation of the colon and abdominal pain.